Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Curr Treat Options Psychiatry. 2014 Mar 22;1(2):107–120. doi: 10.1007/s40501-014-0010-9

Figure 1.

Figure 1

Schematic model of the glutamate synapse, showing binding sites for glycine (Gly) and D-serine (D-ser), along with Type 1 glycine transporters (Gly T) that represent a target for drug development. Other targets include metabotropic type 2/3 (mGlu 2/3) or type 5 (mGlu 5), or D-amino acid oxidase (DAAO). (Used with permission from Moghaddam, B. and D. Javitt, From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology, 2012. 37(1): p. 4–15.)